Infliximab for the treatment of CNS sarcoidosis: A multi-institutional series

Conclusions: Most patients with CNS sarcoidosis treated with infliximab exhibit favorable imaging and clinical treatment responses, including some previously refractory to other immunosuppressive treatments. Classification of evidence: This study provides Class IV evidence that for patients with CNS sarcoidosis infliximab is associated with favorable imaging and clinical responses.

http://www.neurology.org/cgi/content/short/89/20/2092?rss=1

Source: Neurology - November 13, 2017 Category: Neurology Authors: Gelfand, J. M., Bradshaw, M. J., Stern, B. J., Clifford, D. B., Wang, Y., Cho, T. A., Koth, L. L., Hauser, S. L., Dierkhising, J., Vu, N., Sriram, S., Moses, H., Bagnato, F., Kaufmann, J. A., Ammah, D. J., Yohannes, T. H., Hamblin, M. J., Venna, N., Green Tags: All Immunology ARTICLE Source Type: research